Sign in Subscribe

kras

A collection of 33 issues

Furin Inhibition Targets KRAS and BRAF Pathways

Skip to content The CRC Digest Furin Inhibition Targets KRAS and BRAF Pathways Blocking Furin improved chemotherapy sensitivity in KRAS- and BRAF-mutant organoids. (Oncogene) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

CRC Research Finding

Skip to content The CRC Digest ◇ Furin Protein Sustains Tumor Signals in KRAS- and BRAF-Mutated Colorectal Cancer Preclinical research identifies Furin as a key mediator of the TGF-β1-COX-2 pathway in KRAS- and BRAF-mutant colorectal cancer; blocking Furin suppressed tumor growth and enhanced sensitivity to chemotherapy in organoid models. (Oncogene) This

This Week in CRC Research — July 12, 2026

Weekly colorectal cancer research intelligence

KRAS, NRAS, and BRAF mutation patterns in Chile

Skip to content The CRC Digest KRAS, NRAS, and BRAF mutation patterns in Chile Real-world data from 999 Chilean patients characterized the frequency and sex-specific distribution of KRAS, NRAS, and BRAF mutations. (Journal of Gastrointestinal Oncology) This content is informational only and does not constitute medical advice. Always consult your

CRC Research Update — July 06, 2026

Today's colorectal cancer research highlights

CRC Research Finding

Skip to content The CRC Digest Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease) This content is informational only and does not constitute medical advice. Always consult your oncologist or

New FAK inhibitor shows promise in KRAS-mutant colorectal cancer

Skip to content The CRC Digest New FAK inhibitor shows promise in KRAS-mutant colorectal cancer Researchers designed a focal adhesion kinase (FAK) inhibitor (compound 7g) that demonstrated antiproliferative activity in KRAS-mutant HCT116 colorectal cancer cells and showed 66.5% tumor growth inhibition in mouse models. (Bioorg Chem) This content is

CRC Research Update — July 02, 2026

Today's colorectal cancer research highlights

KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery

Skip to content The CRC Digest KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery In 190 patients who had curative liver surgery for colorectal metastases, KRAS mutations (37.9% of patients) were associated with significantly worse overall and recurrence-free survival and more aggressive recurrence patterns. (Surgery Today) This content

CRC Research Update — June 25, 2026

Today's colorectal cancer research highlights